ArticleEmerging infectious diseases2021
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Clinical characteristics and associated factors of macrolide-resistant mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Pooled it
- Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Risk factors for plastic bronchitis complicating severeTranslational pediatrics · 2026Article
- Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.The Journal of infectious diseases · 2026Article
- Advances in treatment and prevention of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in children.Pediatric research · 2026Review
- Prevalence of Macrolide-resistant Mycoplasma pneumoniae in Children and Adolescents With Community-acquired Pneumonia: A Prospective Study in Thailand.The Pediatric infectious disease journal · 2026Article
- Routine admission biomarkers for identifying co-infection and stratifying severity in pediatric macrolide-resistantTranslational pediatrics · 2026Article
- A fever-based therapeutic window for bronchoscopy to prevent bronchiolitis obliterans in children with Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children.Frontiers in pediatrics · 2026Article
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Doxycycline vs levofloxacin for macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a real-world study from China.Italian journal of pediatrics · 2025Observational
- Macrolide-resistant Mycoplasma pneumoniae pneumonia in Chinese children: a retrospective study of clinical features and prognosis.Italian journal of pediatrics · 2025Article
- Clinical characteristics of mycoplasma pneumoniae pneumonia in children with 23 S rRNA mutations in domain V and exploration of the timing of glucocorticoid therapy.BMC infectious diseases · 2025Article
- Whole genome sequencing confirmed theASM case reports · 2025Article
- Article
- An mRNA Vaccine Targeting the C-Terminal Region of P1 Protein Induces an Immune Response and Protects AgainstInternational journal of molecular sciences · 2025Article
- Evolution and characteristics of tetracycline resistance inMicrobiology spectrum · 2025Article
- Quality and reliability of pediatric pneumonia related short videos on mainstream platforms: cross-sectional study.BMC public health · 2025Article
- Treatment modalities for fever duration in children with Mycoplasma pneumoniae pneumonia.Scientific reports · 2025Article
- Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA.Emerging infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in Ohio, USA. We cultured PCR-positive M. pneumoniae specimens and sequenced M. pneumoniae-positive cultures to detect macrolide resistance mutations. We reviewed medical records to compare characteristics of both groups. We identified 14 (2.8%) MRMp and 485 (97.2%) MSMp samples. Patients in these groups had similar demographics and clinical characteristics, but patients with MRMp had longer hospitalizations, were more likely to have received previous macrolides, and were more likely to have switched to alternative antimicrobial drugs. MRMp-infected patients also had ≈5-fold greater odds of pediatric intensive care unit admission. Rates of MRMp infections in children in central Ohio are low, but clinicians should remain aware of the risk for severe illness caused by these pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.